In 2025, Concord Biotech completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Concord Biotech has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 |
|---|---|---|
Total Scope 1 | 12.511a | 14,340.18a |
Total Scope 2 | ||
Unspecified Calculation Method | 0.023a | 42,409.68a |
Total Scope 3 | N/A | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0.0891a | 117.5951a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Concord Biotech amounted to 12.534 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Concord Biotech decreased by 99.98%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of Concord Biotech were 12.511 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2024), Concord Biotech's Scope 1 emissions decreased by 99.91%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Concord Biotech reported Scope 2 greenhouse gas (GHG) emissions of 0.023 tCO₂e without specifying the calculation method.a
Compared to the previous year (2024), Concord Biotech's Scope 2 emissions (Unspecified Calculation Method) fell by 100% in 2025, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2025, Concord Biotech reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Concord Biotech reported Scope 1 greenhouse gas (GHG) emissions of 12.511 tCO₂e and total revenues of USD 140 millions. This translates into an emissions intensity of 0.09 tCO₂e per millions USD.a
In 2025, Concord Biotech reported a Scope 1 emissions intensity of 0.09 tCO₂e per millions USD. Compared to the peer group median of 13.51, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Concord Biotech ranked 2 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Concord Biotech among the top performers, with one of the lowest emissions intensities relative to peers.a